Patrick Duxbury
Patrick is a Partner at Wragge Lawrence Graham & Co and Head of their Life Sciences Team. Originally a microbiologist and geneticist, he re-qualifyied as a lawyer in 1993 with First Class Honours.
Patrick specialises in all aspects of non-contentious intellectual property law in the life sciences sector. Transactions include several licensing and collaboration deals for biotech and pharmaceutical company clients such as BioXell, Cambridge Antibody Technology Group, Astex Therapeutics, Eisai, PanGenetics, Prosidion, The Wellcome Trust, Renovo and others.
He acted for BioXell in relation to their in-licensing transaction with Lay Line Genomics and he acted for Astex Therapeutics in their widely publicised licence and collaboration deals with AstraZeneca and Novartis. Patrick also acted for Eisai on its recently announced acquisition of the European rights to the intrathecal painkiller, Prialt, from Elan and for The Wellcome Trust in its collaboration with GSK.
Patrick has also advised in relation to recent fundraisings by Domantis and Chroma Therapeutics, the MBO by Close Brothers Private Equity of Rosemont Pharmaceuticals and on several spin outs for clients such as the Medical Research Council and Kings College London.
Patrick is on the editorial board of Pharmaceutical Law Insight and is a member of the Intellectual Property Committee of the Association of the British Pharmaceutical Industry (ABPI). He is described by Legal 500 2010 as a "first-rate IP attorney" and praised in Chambers 2011 for being "totally in command of his subject matter and has built a great team around him."
